



# REGIONAL ADULT PARENTERAL DRUG MONOGRAPH

GENERIC NAME

## DOBUTamine



**Effective Date:** Dec 2011

**Revised Date:** Dec 2022

CLASSIFICATION

**Sympathomimetic  
Adrenergic Agonist**

OTHER NAMES

**Dobutrex**

PAGE

1 of 2

**ADMINISTRATION POLICY:**

**IV Infusion** Administration restricted to nurses experienced in ED/CARDIAC ROOM/ICU/PACU and  
 Prescriber must be available during the infusion

*IV Bolus* – Not recommended

*IM Injection* – Not to be administered

**RECONSTITUTION/DILUTION/ADMINISTRATION:**

**Available as:** 12.5 mg/mL – 20 mL single dose vial

**IV Infusion: Pump Library:**

Drug Library	Dose Rate	Short Name	Care Unit
Yes	mcg/kg/min	dobu500	Critical Care
Drug	Diluent	Final Volume (VTBI)	Final Concentration
500 mg (40 mL of 12.5 mg/mL)	250 mL normal saline	290 mL	1.724 mg/mL
Clinical Advisory: High Alert			
Low Dose Limit: 0.5 mcg/kg/min		High Dose Limit: 20 mcg/kg/min	

**DOSAGE:**

**Usual:** Start at 2.5 mcg/kg/minute – increase by 1 to 4 mcg/kg/minute every 10 to 30 minutes until desired response

**Rarely:** Doses as low as 0.5 mcg/kg/minute and up to 40 mcg/kg/minute have been used

**Maximum rate:** 20 mcg/kg/minute

**Maximum concentration:** 5 mg/mL

**STABILITY/COMPATIBILITY:**

**Stability of Final Admixture:** 24 hours at room temperature

**Compatibility:** Compatible with D5W, normal saline, combination dextrose/saline solutions, Lactated Ringer



## REGIONAL ADULT PARENTERAL DRUG MONOGRAPH

GENERIC NAME  
**DOBU**Tamine



**Effective Date:** Dec 2011

**Revised Date:** Dec 2022

CLASSIFICATION  
**Sympathomimetic  
Adrenergic Agonist**

OTHER NAMES  
**Dobutrex**

PAGE  
2 of 2

### PRECAUTIONS, POTENTIAL ADVERSE REACTIONS:

- Vesicant, irritant
- Contraindicated in idiopathic hypertrophic subaortic stenosis, pheochromocytoma, uncorrected tachycardia
- Use cautiously in patients with hyperthyroidism, anesthetic agents or other sympathomimetic agents
- Increased blood pressure, heart rate, palpitations, angina
- Nausea, vomiting and bad taste
- Headache, fatigue, paresthesia, anxiety

### ADDITIONAL NOTES AND NURSING CONSIDERATIONS:

- Continuous cardiac monitoring required
- Monitor vital signs
- Peripheral administration may be used only as an interim measure until CVAD is established
- Use caution in patients with sulphite allergy
- Onset of action: less than 2 minutes. Duration: less than 10 minutes.